These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37024412)

  • 81. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.
    Mangat HS; Musah A; Luedtke S; Syed AA; Maramattom BV; Maruthanal J; Bosman A; Kostkova P
    Front Public Health; 2022; 10():972464. PubMed ID: 36311588
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
    Yih WK; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
    Vaccine; 2023 Jan; 41(3):826-835. PubMed ID: 36535825
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.
    Montano D
    Front Public Health; 2021; 9():756633. PubMed ID: 35186864
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
    Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
    Fleming-Dutra KE; Wallace M; Moulia DL; Twentyman E; Roper LE; Hall E; Link-Gelles R; Godfrey M; Woodworth KR; Anderson TC; Rubis AB; Shanley E; Jones JM; Morgan RL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley M; Meyer S; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(26):859-868. PubMed ID: 35771731
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
    Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
    Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination.
    Beatty AL; Peyser ND; Butcher XE; Cocohoba JM; Lin F; Olgin JE; Pletcher MJ; Marcus GM
    JAMA Netw Open; 2021 Dec; 4(12):e2140364. PubMed ID: 34935921
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
    Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
    Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Analysis of COVID-19 mRNA Vaccine-induced Mouth Ulcers Using the Japanese Adverse Drug Event Report Database.
    Onoda T; Tanaka H; Matsuo H; Takigawa M; Satoh M; Ishii T
    Pharmazie; 2023 May; 78(5):63-66. PubMed ID: 37189267
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis.
    Katoto PDMC; Brand AS; Byamungu LN; Tamuzi JL; Mahwire TC; Kitenge MK; Wiysonge CS; Gray G
    Hum Vaccin Immunother; 2022 Nov; 18(6):2144039. PubMed ID: 36367429
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center.
    Brunello A; Guarneri V; Coppola M; Bernardi M; Ottolitri K; Ghi MG; Mioranza E; Vianello F; Gottardi M; Lonardi S; Zagonel V
    Oncologist; 2022 Mar; 27(2):e203-e205. PubMed ID: 35641217
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M
    Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients.
    Naveed Z; Li J; Naus M; Velásquez García HA; Wilton J; Janjua NZ;
    Int J Infect Dis; 2023 Jun; 131():75-78. PubMed ID: 36967038
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
    Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
    Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
    Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety.
    Luo C; Du J; Cuker A; Lautenbach E; Asch DA; Poland GA; Tao C; Chen Y
    Sci Rep; 2022 Jun; 12(1):10946. PubMed ID: 35768434
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events.
    Noh Y; Ko HY; Kim JH; Yoon D; Choe YJ; Choe SA; Jung J; Shin JY
    Epidemiol Health; 2023; 45():e2023054. PubMed ID: 37309115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.